
The target is the system: Condensates biotech aspires to ‘rewrite the rulebook’ on drug discovery
Another biotech has burst into the buzzy but still budding field of biomolecular condensates with $50 million in Series A funding.
Transition Bio, based in both Cambridge, UK, and Cambridge, MA, is looking to bring condensate drug discovery, a field that originated in neuroscience, to cancer. Co-founded by two biophysics professors — David Weitz of Harvard and Tuomas Knowles of the University of Cambridge — the 18-month-old biotech is building a machine learning platform that maps out condensates in what Knowles described as a “phase diagram.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.